Mobia Medical's IPO priced at the $14–$16 midpoint of $15 per share late May 7, implying a roughly $496 million fully diluted market cap, but shares debuted weakly on Nasdaq under ticker MOBI on May 8, opening near $14 before plunging 23% to close around $11.50 amid high volume of over 1.7 million shares. This sharp post-IPO decline reflects trader consensus on the commercial-stage neurostimulation device maker's challenges, including a $46.5 million net loss on $32 million trailing revenue despite FDA approval for its Vivistim Paired VNS system for chronic stroke recovery and recent Medicare reimbursement. With the offering set to close May 11, implied probabilities lock in below $500 million due to biotech sector headwinds and profitability risks; a dramatic rebound would require unforeseen clinical milestones or partnerships, though historical medtech IPO patterns suggest sustained pressure.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano<$500M 100.0%
$500M–$700M <1%
$700M–$900M <1%
$900M+ <1%
$21,457 Wol.
$21,457 Wol.
May 8, 2026
<$500M
Yes
$500M–$700M
No
$700M–$900M
No
$900M+
No
No IPO before July 2026
No
<$500M 100.0%
$500M–$700M <1%
$700M–$900M <1%
$900M+ <1%
$21,457 Wol.
$21,457 Wol.
May 8, 2026
<$500M
$6,131 Wol.
Yes
$500M–$700M
$9,617 Wol.
No
$700M–$900M
$3,317 Wol.
No
$900M+
$1,273 Wol.
No
No IPO before July 2026
$1,119 Wol.
No
This market will resolve based on Mobia Medical's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on May 8 (ET). If no such IPO occurs by June 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before July 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Mobia Medical's IPO priced at the $14–$16 midpoint of $15 per share late May 7, implying a roughly $496 million fully diluted market cap, but shares debuted weakly on Nasdaq under ticker MOBI on May 8, opening near $14 before plunging 23% to close around $11.50 amid high volume of over 1.7 million shares. This sharp post-IPO decline reflects trader consensus on the commercial-stage neurostimulation device maker's challenges, including a $46.5 million net loss on $32 million trailing revenue despite FDA approval for its Vivistim Paired VNS system for chronic stroke recovery and recent Medicare reimbursement. With the offering set to close May 11, implied probabilities lock in below $500 million due to biotech sector headwinds and profitability risks; a dramatic rebound would require unforeseen clinical milestones or partnerships, though historical medtech IPO patterns suggest sustained pressure.
This market will resolve based on Mobia Medical's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on May 8 (ET). If no such IPO occurs by June 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before July 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on May 8 (ET). If no such IPO occurs by June 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before July 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Rynek otwarty: May 5, 2026, 7:06 PM ET
Wolumen
$21,457Data zakończenia
May 8, 2026Rynek otwarty
May 5, 2026, 7:06 PM ETResolver
0x69c47De9D...Wynik zaproponowany: Yes
Brak sporu
Ostateczny wynik: Yes
This market will resolve based on Mobia Medical's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on May 8 (ET). If no such IPO occurs by June 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before July 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Mobia Medical's IPO priced at the $14–$16 midpoint of $15 per share late May 7, implying a roughly $496 million fully diluted market cap, but shares debuted weakly on Nasdaq under ticker MOBI on May 8, opening near $14 before plunging 23% to close around $11.50 amid high volume of over 1.7 million shares. This sharp post-IPO decline reflects trader consensus on the commercial-stage neurostimulation device maker's challenges, including a $46.5 million net loss on $32 million trailing revenue despite FDA approval for its Vivistim Paired VNS system for chronic stroke recovery and recent Medicare reimbursement. With the offering set to close May 11, implied probabilities lock in below $500 million due to biotech sector headwinds and profitability risks; a dramatic rebound would require unforeseen clinical milestones or partnerships, though historical medtech IPO patterns suggest sustained pressure.
This market will resolve based on Mobia Medical's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on May 8 (ET). If no such IPO occurs by June 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before July 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on May 8 (ET). If no such IPO occurs by June 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before July 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Wolumen
$21,457Data zakończenia
May 8, 2026Rynek otwarty
May 5, 2026, 7:06 PM ETResolver
0x69c47De9D...Wynik zaproponowany: Yes
Brak sporu
Ostateczny wynik: Yes
Mobia Medical's IPO priced at the $14–$16 midpoint of $15 per share late May 7, implying a roughly $496 million fully diluted market cap, but shares debuted weakly on Nasdaq under ticker MOBI on May 8, opening near $14 before plunging 23% to close around $11.50 amid high volume of over 1.7 million shares. This sharp post-IPO decline reflects trader consensus on the commercial-stage neurostimulation device maker's challenges, including a $46.5 million net loss on $32 million trailing revenue despite FDA approval for its Vivistim Paired VNS system for chronic stroke recovery and recent Medicare reimbursement. With the offering set to close May 11, implied probabilities lock in below $500 million due to biotech sector headwinds and profitability risks; a dramatic rebound would require unforeseen clinical milestones or partnerships, though historical medtech IPO patterns suggest sustained pressure.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania